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Abstract
Introduction: ARTEMIN (ARTN) is an estrogen regulated growth factor, the expression of which promotes
resistance to antiestrogen therapies and predicts poorer survival outcome of patients with estrogen receptor (ER)
positive mammary carcinoma (ER+MC) treated with tamoxifen. ARTN is also expressed in ER negative mammary
carcinoma (ER-MC). Herein, we determined the role of ARTN in ER-MC and defined the mechanism of action
producing poor patient prognosis.
Methods: We modulated the expression of ARTN in two ER- (mesenchymal/claudin-low) mammary carcinoma cell
lines (BT549 and MDA-MB-231) by forced expression or small interfering RNA (siRNA) mediated depletion. The
effects of modulation of ARTN expression were examined by various in vitro measures of oncogenicity, including
the expression of TWIST1 messenger RNA (mRNA) and protein. In vitro results were correlated to xenograft studies
in immunodeficient mice. Co-expression of ARTN and TWIST1 and their association to poor survival outcome were
examined in a cohort of patients with ER-MC. Pathway analysis was performed by pharmacological inhibition of
phosphorylation of AKT (pAKT-Ser 473) or modulation of TWIST1 expression.
Results: ARTN expression resulted in ER-MC cells with enhanced mesenchymal characteristics, including increased
invasion and a gene expression profile consistent with enhanced mesenchymal phenotype. ARTN stimulated ER-
MC cell anchorage independent and 3D matrigel growth, endothelial cell adhesion and transmigration of ER-MC
cells through an endothelial cell barrier. Forced expression of ARTN produced a larger, locally invasive tumour mass
with tumour emboli that produced distant metastasis. ARTN regulated TWIST1 expression in ER-MC cells and ARTN
expression was significantly correlated to TWIST1 expression in a panel of mammary carcinoma cell lines and in a
cohort of patients with ER-MC. Low expression of both ARTN and TWIST1 predicted 100% relapse free and overall
survival in patients with ER-MC, whereas high expression of both ARTN and TWIST1 was associated with a poor
survival outcome. ARTN stimulated an increase in TWIST1 expression via increased AKT activity. siRNA mediated
depletion of TWIST1 abrogated ARTN stimulated cellular behaviour associated with metastasis, and forced
expression of TWIST1 abrogated the functional effects of ARTN depletion.
Conclusions: ARTN and TWIST1 synergize to produce a worse outcome in ER-MC and combined inhibition of
ARTN and phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) may therefore provide a novel therapeutic
strategy in this subtype of mammary carcinoma.
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Progression of mammary carcinoma is a complex pro-
cess that involves aberrant regulation of multiple signal-
ling pathways [1]. Determination of estrogen receptor
(ER) status of invasive carcinomas before therapeutic
intervention has become standard practice in the man-
agement of mammary carcinoma. Anti-estrogen therapy
has proven to be successful for the treatment of ER-
positive mammary carcinoma (ER+MC), which conse-
quently generally has a better prognosis [2]. Conversely,
ER-negative mammary carcinomas (ER-MC) are more
aggressive and consistently associated with poorer prog-
nosis [2]. Furthermore, based on molecular profiles, at
least four different subtypes of mammary carcinoma
(luminal A, luminal B, human epidermal growth recep-
tor (HER)2-enriched and basal-like) have been identified
[3]. Another mammary carcinoma subtype that has
recently been delineated, termed claudin-low, exhibits
high expression of genes involved in epithelial-mesench-
ymal transition (EMT), such as SNAI1 and TWIST1, and
cancer stem cell-like features [4,5]. Compared with the
luminal, HER2-enriched and basal-like subtypes, clau-
din-low tumors exhibit lower expression of ER, proges-
terone receptor (PR), HER2 and GATA3 and higher
expression of mesenchymal, cell migration and angio-
genesis genes [4]. Clinicopathological analyses also
revealed that claudin-low tumors have poorer prognosis
and may not be managed effectively with existing che-
motherapy regimens [4]. Identification of novel and tar-
getable molecular pathways responsible for propagating
the poor prognosis in ER-MC is therefore warranted.
ARTEMIN (ARTN) is a member of the glial-cell line-
derived neurotrophic factor (GDNF) family of ligands
[6]. ARTN has been reported to promote mammary
[7,8], endometrial [9], lung [10] and pancreatic [11] car-
cinoma progression. ARTN is an estrogen-regulated
gene and it has been demonstrated that ARTN reduces
the efficacy of anti-estrogens in ER+MC [8]. Further-
more, ARTN expression is correlated with decreased
survival of patients with ER+MC treated with tamoxifen.
Importantly, depletion or inhibition of ARTN partially
restores tamoxifen sensitivity in tamoxifen-resistant
mammary carcinoma cells [8].
TWIST1 belongs to the family of basic helix-loop-
helix transcription factors originally found to modulate
the expression of various target genes through canonical
E-box responsive elements [12,13]. Increased expression
of TWIST1 is observed in various human cancers
[5,14,15] including ER-negative and claudin-low mam-
mary carcinoma [4]. Evidence also indicates that
TWIST1 contributes to cancer cell dissemination by
promoting EMT and increasing cellular invasiveness
[16,17]. Furthermore, a recent report suggests that
TWIST1 interacts with several components of the Mi2/
nucleosome remodelling and deacetylase (Mi2/NuRD)
complex including metastasis-associated protein family
member 2 (MTA2). MTA2 is a corepressor of ERa and
increased MTA2 expression leads to estrogen-indepen-
dent growth of mammary carcinoma cells during mam-
mary carcinoma progression and metastasis [18].
Progression from estrogen dependence to estrogen
independence (anti-estrogen resistance) in mammary
carcinoma involves the altered expression of one or
more estrogen-regulated gene networks [19,20]. In addi-
tion to ARTN stimulation of ER-transcriptional activity
and the expression of estrogen-responsive genes, we
have previously demonstrated that ARTN also promotes
estrogen-independent growth of ER+MC cells [8].
ARTN may therefore possess a functional role in ER-
MC. Indeed, in a cohort of patients [21], not only was
ARTN expression correlated with worse survival out-
come in ER+MC patients [8], it also predicted worse
survival outcome in ER-MC patients. Such observations
prompted us to examine the role of ARTN in ER-MC.
We report herein that ARTN stimulates oncogenicity
and metastasis of ER-MC cells via expression of TWIST1
and that functional interaction between ARTN and
TWIST1 promote a worse survival outcome in ER-MC.
Materials and methods
Cell culture
Cell lines used in this study were obtained from the Amer-
ican Type Culture Collection and cultured as recom-
mended. BT549-ARTN and BT549-VEC cells have been
previously described [7]. MDA-MB-231 cells were stably
transfected with pIRESneo3-ARTN or the empty pIRES-
neo3 vector plasmids [7] to generate MDA-MB-231-
ARTN and the control MDA-MB-231-VEC cells, respec-
tively. Similarly, MDA-MB-231 and BT549 cells were sta-
bly transfected with pSilencer-siARTN B and pSilencer-
CK plasmids [8] to obtain MDA-MB-231-siARTN,
BT549-siARTN and MDA-MB-231-siCONT, BT549-
siCONT cells, respectively. BT549 and MDA-MB-231 cell
pairs were transiently transfected with 20 nM stealth
siRNA TWIST1 or universal negative control (Invitrogen,
Carlsbad, CA, USA) using Lipofectamine 2000™ for 24
hours and functional assays performed as described below.
Reagents
Tetramethylrhodamine isothiocyanate phalloidin was pur-
chased from Sigma (St. Louis, MO, USA). AKT inhibitor IV
was purchased from Calbiochem (San Diego, CA, USA).
Quantitative PCR
Quantitative PCR (qPCR) was performed as described
earlier [8,22,23]. In addition SNAI2 primers used for
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CAAG-3’ and reverse 5’-TGACCTGTCTGCAAAT
GCTC-3’. SPARC primers used for qPCR were forward
5’-AGCACCCCATTGACGGGTA-3’ and reverse: 5’-
GGTCACAGGTCTCGAAAAAGC-3’.F o rt h ein vivo
xenograft, the following primers were used: hHPRT for-
ward 5’-TTCCTTGGTCAGGCAGTATAATCC-3’ and
reverse 5’-AGTCTGGCTTATATCCAACACTTCG-3’
mgapdh forward 5’-CTCACTCAAGATTGTCAGC
AATG-3’ and reverse 5’-CACATTGGGGGTAGGAA
CAC-3’.
Immunoblotting and immunofluorescence
Western blot analysis was performed as described earlier
(Liu and Lobie, 2007 [7]) using the following antibodies:
goat anti-ARTN polyclonal antibody (R&D Systems,
Minneapolis, MN, USA), mouse anti-b-ACTIN mono-
clonal antibody (Sigma, St Louis, MO, USA), rabbit
anti-TWIST1 polyclonal an t i b o d y( S a n t aC r u z ,C A ,
USA), rabbit anti-Akt polyclonal antibody and rabbit
anti-p-Akt polyclonal antibody (Cell Signaling Technol-
ogy, Beverly, MA, USA). Immunofluorescent (IF) ima-
ging was performed as previously described [9] using
goat anti-TWIST1 antibody. F-actin was visualised and
IF localisation was performed as previously described [9]
using goat anti-TWIST1 antibody (Santa Cruz, CA,
USA).
Cell function assays
Soft agar colony formation assay, 3D cell growth, cell
migration and invasion assays were performed as pre-
viously described [7]. For monolayer cell proliferation,
3,000 cells were seeded into 100 μlm e d i a( 2 %F B S )a n d
every 24 hours viability was quantified by alamarBlue
(Invitrogen, Carlsbad, CA, USA) as described previously
[8]. Colony scattering assays were performed as pre-
viously described [23]. Endothelial cell adhesion assay
was performed as described previously [24], with minor
modifications, as 5 μM CFMDA cell tracker green (Invi-
trogen, Carlsbad, CA, USA) was used to label cells.
Adherent cells were observed and photographed under a
fluorescence microscope (Olympus, Tokyo, Japan).
Fluorescence was measured with excitation wavelength
at 492 nm and emission wavelength at 517 nm. The
trans-migration assay was performed as described pre-
viously [25].
Metastatic seeding assay
A l la n i m a lw o r kw a sc o n d u c t e di na c c o r d a n c ew i t ha
protocol approved by the institutional animal care and
ethics committee. Tumor growth and metastasis assays
were performed as mentioned earlier [7,26,27]. For
direct tail vein injection, Balb/c nude mice (Shanghai
Slaccas Co., Shanghai, China) (four to six weeks old)
were used. A 1.5 × 10
6 sample of viable BT549-VEC
and BT549-ARTN cells (n = 7 for each group) were
washed and harvested in PBS and subsequently injected
into the lateral tail vein in a volume of 0.1 ml. A 3 ×
10
6 sample of viable MDA-MB-231-VEC and MDA-
MB-231-ARTN cells were injected subcutaneously into
the mammary fat pad of immunodeficient nude mice (n
= 6 for each group). After four weeks, mice were eutha-
nized and lungs and livers were surgically resected for
histology. Tissue samples were either fixed in 4% paraf-
ormaldehyde-PBS (pH = 7.4), embedded in paraffin and
6 μm-thick sections cut (for histological studies with
hematoxylin and eosin) or were frozen at -80°C in RNA-
Later (Ambion, TX, USA) for RNA extraction and qPCR
analysis.
Histopathological analysis
Tissue samples were collected from 94 ER-negative
female mammary carcinoma patients attending the First
Affiliated Hospital of Anhui Medical University (Hefei,
P. R. China) presenting between 2001 and 2002. Institu-
tional ethics committee approval for the project was
obtained before commencement of the study and was in
compliance with the Helsinki Declaration. Written
informed consent was obtained from all patients. Of 94
patients, 33 were HER-2 positive and the remaining 61
were HER-2 negative as described in the additional file
1. All 94 patients underwent radical mastectomy. All
patients had no previous diagnosis of carcinoma, no dis-
tant metastasis at the time of diagnosis, and no evidence
of disease within one month after primary surgery. All
patients received adjuvant chemotherapy (CMF regimen:
cyclophosphamide, 600 mg/m
2 iv bolus, d1,8; metho-
trexate, 40 mg/m
2 iv bolus, d1,8; 5-fluorouracil, 600 mg/
m
2 iv infusion, d1,8; every four weeks for six cycles).
Patients who had undergone chemotherapy or radiation
therapy before surgery were excluded from this study.
Of 94 patients, 76 possessed full follow-up data ranging
from 5 to 64 months, with a median time of 60.0
months and a mean time of 44.7 months.
Immunohistochemical (IHC) analysis of paraffin-
embedded specimens was performed as described pre-
v i o u s l y[ 7 ] .I nb r i e f ,3μm thick tissue microarray
(TMA) sections were deparaffinised in xylene, rehy-
drated in a graded series of ethanol solutions, and
heated in a microwave oven in 0.01 M sodium citrate
buffer (pH 6.0) for 10 minutes for antigen retrieval.
Anti-ARTN antibody (rabbit) (Abcam, CAM, UK) was
used at 1:100 dilution. The scoring procedure is outlined
in additional file 1.
Statistics
All numerical data are expressed as mean ± standard
error of the mean from a representative experiment
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assessed by Student’s t-test (P < 0.05 was considered as
significant) using Microsoft Excel XP (bar graphs) unless
otherwise indicated (chi-squared test). Cox regression
analysis was performed to determine the association of
ARTN and TWIST1 expression to the risk of relapse
and death.
Results
Forced expression of ARTN altered the morphology of ER-
MC cells in vitro
To determine the functional consequences of ARTN
expression in ER-MC, we generated stable cell clones
with forced expression of ARTN in BT549 and in
MDA-MB-231 cells (mesenchymal/claudin low cell
lines) as previously described [7] [see additional file 2a].
Forced expression of ARTN in both BT549 and MDA-
MB-231 cells resulted in a more scattered, elongated
and mesenchymal cellular morphology in monolayer
adherent culture as compared with the respective con-
trol VEC cells (Figure 1a) and as previously reported for
BT549 cells [7]. In colony-scattering assays, we observed
a significantly larger proportion of scattered cells (45%
and 50% more than VEC cells) with forced expression
of ARTN in both BT549 and MDA-MB-231 cells,
respectively (Figure 1b) [see additional file 2b]. Visuali-
sation of the filamentous actin (f-actin) cytoskeleton by
fluorescence microscopy demonstrated that BT549-
ARTN cells exhibited fewer, and more diffuse stress
fibres with accumulation of f-actin at the cell periphery
coinciding with the leading edges of the cell. In contrast,
f-actin in BT549-VEC cells displayed a well-organised
cortical ring near the cell periphery with a regular
appearance of stress fibres similar to the parental cells.
Similar reorganisation of the f-actin cytoskeleton was
also observed in MDA-MB-231-ARTN cells (Figure 1c)
[see additional file 2c]. When cultured in 3D matrigel,
BT549-VEC cells produced circumscribed colonies,
whereas BT549-ARTN cells exhibited more loose colo-
nies as compared with the BT549-VEC cells [see addi-
tional file 2d]. Furthermore, a substantial number of
BT549-ARTN cells spread from the main bulk of the
colony, suggesting that ARTN promoted local invasive
behavior. We also observed similar but less pronounced
effects in MDA-MB-231-ARTN cells when cultured in
3D matrigel [see additional file 2d].
During the progression of carcinoma toward a less dif-
ferentiated and more metastatic state, cells lose their
epithelial characteristics and acquire a mesenchymal
morphology, together with concomitant changes in gene
expression [28]. Such a phenotypic conversion is
referred to as EMT. Based on the changes in cell mor-
phology observed with forced expression of ARTN,
qPCR was therefore performed to determine the effects
of forced expression of ARTN on the relative expression
levels of key genes involved in EMT, cell invasion and
metastasis. qPCR analysis of gene expression in BT549-
ARTN and MDA-MB-231-ARTN cells demonstrated
significantly decreased mRNA expression of the epithe-
lial markers E-CADHERIN (CDH1), g-CATENIN
(CTNNG), and b-CATENIN (CTNNB1). Decreased
OCCLUDIN (OCLN) mRNA expression was also
observed in BT549-ARTN cells but not in MDA-MB-
231-ARTN cells. Increased mRNA expression of
mesenchymal markers TWIST1 and SPARC was
observed in BT549-ARTN and MDA-MB-231 cells,
whereas VIMENTIN (VIM)a n dS L U G( SNAI2)m R N A
expression was increased in BT549-ARTN cells (Table
1). The expression of TWIST1 mRNA in BT549-ARTN
cells was increased 5.4-fold compared with control VEC
cells and in MDA-MB-231-ARTN cells TWIST1 expres-
sion was increased by 4.5-fold compared with the VEC
cells. Increased TWIST1 expression is correlated with an
increased metastatic potential in mammary carcinoma
cells [17,29]. Forced expression of ARTN consistently
increased the mRNA level of the metastasis tumor-asso-
ciated protein2 (MTA2) and NFKB1 in both cell pairs.
Increased expression of MTA2 leads to estrogen inde-
pendent growth of human mammary carcinoma cells
[30] and increased expression of NFKB1 expression
increases the invasive potential of carcinoma cells [31].
Furthermore, increased mRNA expression of NME1,
MMP9 and MYC was observed in BT549-ARTN cells
and MMP2 mRNA expression was increased in MDA-
MB-231-ARTN cells, as compared with the respective
control VEC cells. Thus, autocrine production of ARTN
in ER-MC cells resulted in decreased expression of
epithelial markers and increased expression of mesench-
ymal and metastatic related markers.
Depletion of endogenous ARTN significantly alters the
morphology of ER-MC cells in vitro
We next depleted BT549 and MDA-MB-231 cells of
endogenous ARTN with small interfering RNA (siRNA)
[8] [see additional file 2a] and examined the effects of
depletion of ARTN on cellular morphology. In mono-
layer adherent culture, BT549-siARTN and MDA-MB-
231-siARTN cells exhibited a coherent and relatively
enhanced epithelial cellular morphology compared with
cells with scrambled control siRNA (Figure 1a). In col-
ony-scattering assays, we observed a significantly larger
proportion of BT549-siARTN and MDA-MB-231-
siARTN cells contained in compact colonies (200% and
480% more than siCONT cells) respectively (Figure 1b)
[see additional file 2b]. Visualisation of f-actin by fluor-
escence microscopy demonstrated that cells with siRNA
mediated depletion of ARTN possessed f-actin that was
highly abundant and less diffuse within the cytoplasm of
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nounced cortical organisation of actin filaments and
peripheral localisation of f-actin was rarely observed
(Figure 1c) [see additional file 2c]. When cultured in 3D
matrigel the morphology of colonies formed by BT549-
siARTN cells in matrigel differed from that of BT549-
siCONT cells. ARTN-depleted BT549-siARTN cells
formed smaller and less numerous colonies, whereas the
control BT549-siCONT cells formed colonies similar to
BT549-VEC cells. We also observed similar effects in
MDA-MB-231-siARTN cells, when cultured in 3D
matrigel [see additional file 2d]. Therefore, siRNA
mediated depletion of endogenous ARTN in ER-MC
cells enhanced the epithelial characteristics of these
cells.
ARTN stimulates the oncogenicity and invasion of ER-MC
cells in vitro
Increase in cellular invasiveness and resistance to anoi-
kis are key components of metastasis [32]. Forced
expression of ARTN significantly promoted monolayer
proliferation, colony formation in soft agar [see
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Figure 1 ARTEMIN (ARTN) modulates cellular morphology of estrogen receptor (ER) negative mammary carcinoma (ER-MC) cells. (a)
Monolayer adherent morphology of BT549 and MDA-MB-231 cells with forced expression or depletion of ARTN. Cultures were imaged at
approximately 40% confluence and under 400 × magnification (Bar represents 20 μm). (b) BT549-ARTN and MDA-MB-231-ARTN cells with their
respective vector (VEC) cells and BT549-siARTN and MDA-MB-231-siARTN with their control (siCONT) cells were seeded at a very low cell density
(1000 cell plated in 10 cm petri dish). Colonies formed by each cell types, were categorized and counted as per the extent of colony scattering.
Percentages of each colony category in the total counts were plotted as indicated. (c) ARTN modulates organization of filamentous actin as
visualised by fluorescein isothiocyanate (FITC) - phalloidin in BT549 and MDA-MB-231 cells with forced expression or depletion of ARTN
compared with the respective control cells. Bar, 50 μm (f-actin staining for BT549-ARTN cells), 62.7 μm (f-actin staining for MDA-MB-231-ARTN
cells). *, P < 0.05; **, P < 0.01.
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migration and invasion in transwell assays compared
with their respective control BT549-VEC and MDA-MB-
231-VEC cells (Figures 2a to 2c). BT549-ARTN and
MDA-MB-231-ARTN cells showed a 35% and 22%
increase in monolayer proliferation, 102% and 60%
increase in soft agar colony formation, 479% and 170%
increase in 3D matrigel growth, 249% and 160% increase
in cell migration and 196% and 134% increase in cell
invasion as compared with the control VEC cell lines,
respectively and as previously reported in BT549 cells [7].
Concordantly, BT549-siARTN and MDA-MB-231-
siARTN cells significantly inhibited monolayer prolifera-
tion by 23% and 17%, soft agar colony formation by 48%
and 38% [see additional files 3c and 3d], 3D matrigel
growth by 50% and 40%, cell migration by 31% and 27%
and cell invasion by 38% and 40% as compared to the
siCONT cells respectively (Figures 2d to 2f).
ARTN enhances metastatic seeding of ER- MC cells in vivo
In our xenograft model, BT549 cells failed to form con-
sistent tumor masses. Therefore, to determine whether
ARTN contributes to the metastatic ability of ER-MC
cells, we injected BT549-ARTN cells into the tail vein of
immunodeficient nude mice and examined their ability
to form pulmonary and hepatic metastasis compared
with the control VEC cell line. Metastatic nodules were
readily detectable by histology in the lungs of all mice
(n = 7), four weeks after injection with BT549-ARTN
cells, whereas pulmonary metastases were detected in
only three of seven mice injected with BT549-VEC cells.
The nodules formed in the lungs of animals injected
with BT549-ARTN cells gave rise to, on average, more
than three nodules per lung (Figureas 3a, left panel and
3b, left panel) as compared with less than one nodule
per lung on average in animals with BT549-VEC cells.
A higher frequency of liver metastasis was also observed
in mice injected with BT549-ARTN cells (n =4 )c o m -
pared with mice injected with BT549-VEC cells (n =1 )
[see additional file 4a].
We extracted RNA from lung and liver of mice
injected with BT549-ARTN cells or BT549-VEC cells
and performed qPCR to quantitate the relative expres-
sion of human HPRT (hHPRT) mRNA in the respective
organs. We observed that the level of hHPRT mRNA
expression was increased three-fold in lung and 1.3-fold
in liver in animals injected with BT549-ARTN cells
compared with BT549-VEC cells. Mouse gapdh
(mgapdh) was used as an internal control (Figure 3c, left
panel).
Both MDA-MB-231-VEC and MDA-MB-231-ARTN
cells formed palpable and measurable tumors when
Table 1 Effects of forced expression of ARTEMIN (ARTN) in estrogen receptor (ER) negative mammary carcinoma (ER-
MC) cells on expression of genes functionally involved in epithelial-mesenchymal transition (EMT) and metastatic
progression
BT549 MDA-MB-231
Gene Function Gene Fold change p-value Fold change p-value
Epithelial CTNNB1 0.48 1.60E-03 0.47 1.25E-03
CTNNA1 1.3 8.71E-03 0.68 5.80E-04
CTNNG 0.52 8.23E-03 0.46 1.58E-02
OCLN 0.35 9.71E-04 0.94 2.07E-02
CDH1 0.12 4.93E-02 0.21 4.94E-03
Mesenchymal SNAI2 1.68 6.26E-03 1.1 1.67E-02
VIM 2.44 9.39E-04 1.23 6.79E-03
TWIST1 5.49 3.98E-03 4.56 3.99E-03
SPARC 1.82 2.03E-02 2.35 6.39E-03
Metastatic NME1 2.7 1.57E-02 1.09 1.53E-03
PLAU 1.02 4.40E-04 0.85 1.57E-03
MMP9 2.11 3.64E-02 0.49 1.44E-03
MET 0.85 1.70E-02 0.76 3.10E-03
MMP2 1.04 2.07E-02 4.17 1.54E-03
MTA2 3.02 8.75E-03 1.58 1.49E-02
MMP1 1.29 4.36E-03 0.58 2.18E-02
NFKB1A 2.23 7.19E-03 1.02 3.49E-03
NFKB1 2.77 1.73E-02 1.7 3.96E-03
ERBB2 1.24 1.71E-03 0.96 5.05E-03
MYC 3.55 3.97E-04 0.95 1.40E-03
Results are represented as the fold change in messenger RNA (mRNA) levels in BT549-ARTN or MDA-MB-231-ARTN cells relative to the respective VEC cells.
Values less than one indicates decreased expression and more than one indicates increased expression of the specific mRNA.
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Page 6 of 20injected into the mammary fat pad of immunodeficient
nude mice. Tumors formed by MDA-MB-231-ARTN
cells were larger than those formed by control MDA-
MB-231-VEC cells [see additional file 4b] (Figure 3b,
middle panel). Pulmonary metastases were readily
detectable by histology in the lungs of all mice (n =6 )
four weeks after injection with MDA-MB-231-ARTN
cells and in only five of the six mice injected with
MDA-MB-231-VEC cells (Figure 3a, right panel and 3b,
right panel). MDA-MB-231-ARTN cells gave rise to, on
average, more than 15 nodules per section of lung as
compared with approximately four nodules on average
in animals with MDA-MB-231-VEC cells. We also
extracted RNA from lung and liver of mice injected
with MDA-MB-231-ARTN cells or MDA-MB-231-VEC
cells and performed qPCR to quantitate the relative
expression of hHPRT mRNA in the respective organs.
We observed that the level of hHPRT mRNA expression
was increased two-fold in lung and 1.2-fold in liver in
animals injected with MDA-MB-231-ARTN cells com-
pared with MDA-MB-231-VEC cells (Figure 3c, right
panel). These results indicate that ARTN contributes to
the metastatic potential of ER-MC cells.
Expression and correlation of endogenous ARTN and
TWIST1 in different mammary carcinoma cell lines
qPCR gene expression data demonstrated that forced
expression of ARTN increased TWIST1 mRNA expres-
sion in both BT549 and MDA-MB-231 cells. Previous
studies have demonstrated that TWIST1 is an important
regulator of mammary carcinoma cell EMT and tumor
metastasis [17]. To determine a potential molecular
mechanism underlying ARTN stimulated invasion and
metastasis of ER-MC cells, we therefore investigated the
effects of forced expression and depletion of ARTN on
the expression of TWIST1 protein. As observed in Fig-
ure 4a, TWIST1 protein expression was increased in
both BT549-ARTN and MDA-MB-231-ARTN cells
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Figure 2 ARTEMIN (ARTN) modulates cellular oncogenicity and motility of estrogen receptor (ER) negative mammary carcinoma (ER-
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(qPCR) was performed to measure the messenger RNA (mRNA) expression of human hypoxanthine-guanine phosphoribosyltransferase (hHPRT)i n
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Page 9 of 20compared with respective control VEC cells. Concor-
dantly, BT549-siARTN and MDA-MB-231-siARTN cells
exhibited decreased expression of TWIST1 protein com-
pared with the respective siCONT cells. IF microscopy
of BT549-ARTN cells also demonstrated increased
TWIST1 protein expression as compared with the
BT549-VEC cells with TWIST1 being predominantly
nuclear localized as previously reported [33]. Concor-
dantly, BT549-siARTN cells exhibited decreased
TWIST1 protein expression by IF as compared with the
siCONT cells respectively (Figure 4b).
We next performed qPCR in two immortalised but
otherwise normal human mammary epithelial cells and
10 different human mammary carcinoma cell lines of
differing invasive potential. qPCR gene expression data
showed low expression of both ARTN and TWIST1
mRNA in the two normal mammary epithelial cell lines.
Both ARTN and TWIST1 mRNA were ubiquitously
expressed across different mammary carcinoma cell
lines and increased ARTN and TWIST1 mRNA expres-
sion correlated with a more invasive cell phenotype (Fig-
ure 4c). To further confirm the correlation of ARTN
mRNA expression with TWIST1 mRNA expression, we
compared the relative expression of ARTN mRNA and
TWIST1 mRNA. We observed that TWIST1 mRNA
expression was positively correlated with ARTN mRNA
expression (Pearson coefficient: 0.68) (Figure 4d).
Co-expression of ARTN and TWIST1 in ER-MC predicts
survival outcome
We next determined ARTN and TWIST1 protein
expression in a cohort of human ER-MC by IHC and
examined the association of expression with survival
outcome (relapse free survival (RFS) and overall survival
(OS)). IHC analysis showed that both ARTN and
T W I S T 1p r o t e i nw e r eh i g h l ye x p r e s s e di nE R - M C( F i g -
ure 5a). All 94 samples were positive for TWIST1
expression. We therefore stratified the samples accord-
ing to the level of TWIST1 expression into two cate-
gories (low TWIST1 and high TWIST1 expression).
ARTN immunoreactivity was stratified according to
level of expression into four categories (negative (-),
weak (+), moderate (++) and strong (+++) expression)
[see additional file 1]. Of those tumors negative for
ARTN expression, 60% exhibited strong TWIST1
expression. However, with increasing expression of
ARTN in tumors, there was a concordant graded
increase in TWIST1 expression with 86.7% of tumors
with strong ARTN expression also exhibiting high
TWIST1 expression. To further confirm the correlation
of expression between TWIST1 and ARTN in mammary
carcinoma, we compared the relationship by Spearman’s
rank correlation coefficient and found a significant posi-
tive value (Spearman correlation: rs =0 . 2 1 ,P =0 . 0 3 )
(Table 2). Hence, TWIST1 expression in ER-MC is par-
tially correlated with ARTN expression.
We analyzed survival outcome of patients with tumors
with either low or high ARTN or TWIST1. ARTN low
tumors were defined as those with negative or weak
expression of ARTN and ARTN high tumors exhibited
moderate or strong expression of ARTN. Tumors with
high ARTN expression tended to exhibit decreased RFS
and OS of patients but this tendency did not reach sig-
nificance in this cohort (Figure 5bi) [see additional file
5i]. A significant correlation of high TWIST1 expression
to decreased RFS (P =0 . 0 1 )a n dO S( P = 0.03) of
patients was observed (Figure 5bii) [see additional file
5i].
We subsequently analysed survival outcome in
patients whose tumors exhibited both low ARTN and
low TWIST1 expression compared with those that
exhibited high ARTN and low TWIST1 expression. We
observed that tumors with low TWIST1 and high
ARTN were associated with decreased RFS (P = 0.004)
and OS (P = 0.004) (Figure 5biii) [see additional file 5i]
compared with those with low TWIST1 and low ARTN.
Furthermore multivariate analysis demonstrated a signif-
icant association of ARTN high-TWIST1 low expression
with decreased RFS (odds ratio: 3.4, 95% confidence
interval (0.54-92.95): P = 0.03) and OS (odds ratio: 3.6,
95% confidence interval (0.55-99.84): P =0 . 0 2 )a tf i v e
years compared with low ARTN-low TWIST1 expres-
sion (Table 3). Compared with tumors with low ARTN
and low TWIST1 expression, tumors that exhibited
both high ARTN and high TWIST1 expression were
associated with worse RFS (P = 0.002) and OS (P =
0.005) (Figure 5biv) [see additional file 5i]. Furthermore,
tumors with both low ARTN and low TWIST1 expres-
sion exhibited improved survival (RFS 100% (P =0 . 0 0 2 )
and OS 100% (P = 0.005)), compared with low TWIST1
expression alone (RFS 78.3% (P = 0.01) and OS 78.3%
(P = 0.03)) (Figure 5biv) [see additional file 5i] (Figure
5bii) [see additional file 5i]. In addition, multivariate
analysis revealed a significant correlation of high ARTN-
high TWIST1 expression to decreased RFS (odds ratio:
9.2, 95% confidence interval (0.51-163.76): P = 0.01) and
OS (odds ratio: 9.2, 95% confidence interval (0.51-
165.51): P = 0.01) at five years compared with low
ARTN-low TWIST1 expression (Table 3).
TWIST1 mediates ARTN-stimulated oncogenicity and
invasion
To determine the functional significance of ARTN-sti-
mulated TWIST1 expression we employed siRNA to
selectively reduce TWIST1e x p r e s s i o ni nb o t hB T 5 4 9
and MDA-MB-231 cells with or without forced expres-
sion of ARTN. The siRNA targeting TWIST1 efficiently
depleted TWIST1 protein expression in both cell pairs
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Figure 5 Association of ARTEMIN (ARTN) and TWIST1 expression with survival outcome in estrogen receptor (ER) negative mammary
carcinoma (ER-MC). (a) ARTN and TWIST1 expression detected by immunohistochemistry (IHC) in ER-MC samples. ARTN is predominantly
localised to the cytoplasm whereas TWIST1 predominantly localized to the nucleus. 200× magnification. (b) Kaplan-Meier analysis of the
association of ARTN expression (i), TWIST1 expression (ii), low-ARTN and low-TWIST1 vs high ARTN expression and low-TWIST1expression (iii) and
low-ARTN and low-TWIST1 vs high ARTN and high TWIST1 expression (iv); relapse free survival (RFS) in ER-MC patients.
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Page 11 of 20(Figure 6a) whereas transfection of scrambled siRNA
(siCONT) had no effect on TWIST1 expression. Deple-
tion of TWIST1 reduced the basal capacity for mono-
layer proliferation, colony formation in soft agar, 3D
matrigel growth and migration and invasion in Trans-
well assays of BT549-VEC and MDA-MB-23-VEC cells
as previously reported for mammary carcinoma cells
[34]. Depletion of TWIST1 also prevented or largely
abrogated the stimulatory effects of ARTN on mono-
layer proliferation, colony formation in soft agar, 3D
matrigel growth, migration and invasion in transwell
assays in BT549-ARTN and MDA-MB-231-ARTN cells
(Figures 6b to 6f).
ARTN stimulates mammary carcinoma cell attachment to,
and migration through an endothelial cell layer
As observed in Figure 7a, BT549-ARTN and MDA-MB-
231-ARTN cells exhibited increased adherence to
human microvascular endothelial cells (HMEC-1) by
2.8-fold and 2.3-fold as compared with their respective
VEC control cells. Depletion of TWIST1 by siRNA sig-
nificantly inhibited the ARTN stimulated enhancement
of the adhesion of both cell pairs to the endothelial cell
layer. BT549-ARTN and MDA-MB-231-ARTN cells also
exhibited increased trans-migration through an endothe-
lial cell layer by 2.5-fold and 2.0-fold as compared with
their respective VEC control cells. TWIST1 depletion
inhibited this trans-migration in both cell lines with
forced expression of ARTN (Figure 7b).
ARTN promoted oncogenicity is mediated via activation
of AKT in ER-MC cells
It has been previously reported that ARTN activates
AKT to mediate its oncogenic effects in endometrial
carcinoma cells [9]. The AKT signaling pathway has
been reported to promote TWIST1 expression in dif-
ferent carcinoma cells [35,36]. Furthermore, Activation
of AKT and TWIST1 in mammary carcinoma cells has
previously been described [15,37]. We therefore deter-
mined total AKT protein and pAKT (Ser473) levels in
BT549-ARTN and MDA-MB-231-ARTN cells com-
pared with their control VEC cells. BT549-ARTN and
MDA-MB-231-ARTN cells exhibited significantly
increased phosphorylation of AKT (Ser473) compared
with the respective VEC cells without alteration of the
total AKT level. Concordantly, BT549-siARTN and
MDA-MB-231-siARTN cells exhibited diminished
AKT activation compared with the respective siCONT
cells (Figure 8a).
We next evaluated whether signalling through AKT
was required for ARTN stimulated oncogenicity and
invasion in ER-MC cells. Treatment of BT549-VEC
cells with AKT Inhibitor IV decreased the basal levels
of pAKT but did not affect the total AKT level. ARTN
stimulated activation of AKT was also decreased by
AKT inhibitor IV without altering the expression level
of total AKT (Figure 8b). AKT inhibitor IV decreased
the basal level of TWIST1 expression in BT549-VEC
cells and also significantly inhibited ARTN stimulated
TWIST1 expression in BT549-ARTN cells. AKT Inhi-
bitor IV reduced the basal capacity for colony forma-
tion in soft agar, 3D matrigel growth, migration and
invasion in transwell assays of BT549-VEC and MDA-
MB-23-VEC cells. AKT inhibitor IV also eliminated or
largely abrogated the stimulatory effects of ARTN on
colony formation in soft agar, 3D matrigel growth,
migration and invasion in transwell assays in both
BT549-ARTN and MDA-MB-231-ARTN cells (Figures
8c to 8f). Thus, ARTN utilizes AKT to increase
TWIST1 expression and promote oncogenicity and
invasiveness of ER-MC cells.
Table 2 Correlation between ARTEMIN (ARTN) and
TWIST1 expression in estrogen receptor (ER) negative
mammary carcinoma (ER-MC)
TWIST1 expression
Low High
ARTN expression Negative 14 (40%) 21 (60%)
Weak 9 (31%) 20 (69%)
Moderate 3 (20%) 12 (80%)
Strong 2 (13.3%) 13 (86.7%)
Spearman correlation: P = 0.039 rs = 0.214. Expression parameters are
described in details in the Materials and methods section.
Table 3 Multivariate analysis of the association of tumor ARTEMIN (ARTN) and TWIST1 expression with five-year relapse
free (RFS) and overall survival (OS) in patients with estrogen receptor (ER) negative mammary carcinoma (ER-MC)
RFS OS
Odds ratio (95% CI) P Odds ratio (95% CI) P
ARTN-/ARTN+ 1.157 (0.971-1.461) 0.22 1.196 (0.943-1.518) 0.14
TWIST1-/TWIST1+ 1.733 (1.076-2.791) 0.024 1.656 (1.026-2.674) 0.039
Low ARTN-Low TWIST1/High ARTN-Low TWIST1 3.420 (0.542-92.950) 0.029 3.676 (0.556-99.842) 0.024
Low ARTN-Low TWIST1/High ARTN-High TWIST1 9.202 (0.517-163.761) 0.014 9.268 (0.519-165.511) 0.013
CI, confidence interval.
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Figure 6 ARTEMIN (ARTN) mediated oncogenicity is regulated by TWIST1 expression in estrogen receptor (ER) negative mammary
carcinoma (ER-MC) cells. (a) Western blot analysis for TWIST1 in BT549 and MDA-MB-231 cells with forced expression of ARTN ± TWIST1 small
interfering RNA (siRNA) showing efficiency of siRNA-mediated depletion of TWIST1 protein. Universal negative control was used as an internal
control. (b) Monolayer proliferation assay (2% fetal bovine serum media). (c) Colony formation in soft agar: Cells were cultured in 0.35% agar for
10 days. Cell growth was measured using alamarBlue. (d) Cell growth (number) in 3D matrigel: cells were cultured in 3D matrigel for seven days.
Cell growth was detected using alamarBlue. (e) Cell migration and (f) Cell invasion were determined by use of transwell inserts as described in
materials and methods. siRNA control-treated vector (VEC) cells presented as 100%. *, P < 0.05; **, P < 0.01.
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Figure 7 TWIST1 mediates ARTEMIN (ARTN) stimulated attachment to, and migration through, an endothelial cell layer. (a) Forced
expression of ARTN in BT549 and MDA-MB-231 cells promoted adhesion to an endothelial cell layer: Human microvascular endothelial cells1
(HMEC1) were grown to 100% confluence in 96-well plates and 5-chloromethylfluorescein diacetate (CFMDA) cell tracker green (5 μM) labelled
BT549-ARTN and MDA-MB-231-ARTN cells ± TWIST1 siRNA were seeded on top for one hour, washed and counted under a fluorescence
microscope. Bar, 78.4 μm. (b) Forced expression of ARTN in BT549 and MDA-MB-231 cells promoted in vitro trans-migration activity through an
endothelial cell layer: CFMDA labelled cells were seeded on top of HMEC1 cells grown 100% confluence on transwell inserts. After 14 hours
invaded cells were counted under fluorescence microscope. siRNA control-treated vector (VEC) cells presented as 100%. **, P < 0.01; ***, P <
0.001.
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Page 15 of 20ARTN activation of AKT is upstream of TWIST1 mediated
oncogenicity in ER-MC cells
We determined if increased TWIST1 expression could
substitute for the functional effects of ARTN in ER-MC
cells. We generated stable cell clones with forced
expression of TWIST1 in BT549 cells (Figure 9a) using
a Myc tagged-TWIST1 expression vector [34]. Western
blot analysis demonstrated that forced expression of
TWIST1 in BT549 cells did not alter AKT expression
or ARTN expression as compared with the VEC control
cells. Depletion of ARTN by siRNA in BT549-VEC cells
decreased the basal level of pAKT but did not alter total
AKT or TWIST1 expression as compared with BT549-
VEC cells with siCONT (Figure 9a). Depletion of ARTN
by siRNA also decreased pAKT expression in BT549-
TWIST1 cells, without altering AKT or TWIST1
expression as compared with siCONT cells. Thus, the
activation of AKT precedes ARTN stimulated increases
in TWIST1 expression.
We next analyzed the functional effects of siRNA
mediated depletion of ARTN in BT549-TWIST1 cells.
Forced expression of TWIST1 significantly promoted
colony formation in soft agar, 3D matrigel growth,
migration and invasion in transwell assays compared
with the control BT549-VEC cells. BT549-TWIST1 cells
exhibited a 60% increase in soft agar colony formation,
90% increase in 3D matrigel growth, 95% increase in
cell migration and 110% increase in cell invasion (Fig-
ures 9b to 9e) as compared with the BT549-VEC cell
line. Depletion of ARTN by siRNA decreased the basal
level of colony formation in soft agar, 3D matrigel cell
growth, migration and invasion in transwell assays in
BT549-VEC control cells. However, in cells with forced
expression of TWIST1, siRNA mediated depletion of
ARTN exerted no effect. Thus, the functional effects of
ARTN in ER-MC cells are mediated by increased
TWIST1 expression.
Discussion
Mammary carcinoma is a heterogeneous disease, which
comprises a significant fraction of ER negative sub-
classes [38]. Given the poor disease prognosis and survi-
val outcomes associated with ER-MC, delineation of
prognostic markers to allow better identification and
treatment are essential. Herein, we have demonstrated
that ER-MC cells with mesenchymal/low-claudin sub-
type, express high levels of ARTN, which modulate the
metastatic potential of cells by promotion of migratory
and invasive behavior. Although ARTN is an estrogen-
regulated gene [8], several reports have previously
described the mechanisms of action of different growth
factors to support estrogen independence during carci-
noma tumor progression [39-42]. This is concordant
with our previous report which demonstrated that
ARTN promoted estrogen independent growth of ER
+MC cells [8].
ARTN expression has previously been correlated with
poorer survival outcome in mammary carcinoma overall
[7] and in ER+MC patients treated with tamoxifen [8].
Herein, we have demonstrated that a lower expression
of both ARTN and TWIST1 predicted a better survival
outcome (100%) in ER-MC in contrast to either low
expression of ARTN or TWIST1 alone, whereas high
expression of both ARTN and TWIST1 predicted worse
survival. That ARTN was only associated with survival
outcome in ER-MC with low TWIST1 expression, and
that forced expression of TWIST1 negated the effects of
ARTN depletion, suggests that TWIST1 is the predomi-
nant mediator of ARTN function in ER-MC. Inhibition
of ARTN would therefore not be effective as a single
therapy in ER-MC with high TWIST1 expression.
Acquired increased expression of TWIST1 would also
negate the effects of inhibition of ARTN and presum-
ably serve as a mechanism of resistance [43] to pro-
longed use of ARTN inhibitory strategies. However,
based on the results presented herein, inhibition of
ARTN, together with strategies to inhibit TWIST1
expression, such as inhibition of PI3K/AKT [44,45]
would produce a more desirable outcome than use of
either approach alone. Combined inhibition of ARTN
and PI3K/AKT/TWIST1 could therefore represent a
valuable therapeutic approach in ER-MC mammary
carcinoma.
The prometastatic potential of TWIST1 in mammary
carcinoma cells is well established [17,29,33]. Previously
published reports delineating roles of transforming
growth factor (TGF)-b and TWIST1 promoting EMT
and metastasis [5] suggested that ARTN, a TFG-b
superfamily member could also potentially regulate
TWIST1 to promote EMT and metastasis [17]. TWIST1
can be regulated by multiple extracellular factors
through PI3K/AKT, Wnt1 and NF-B pathways in inva-
sive carcinoma [46-48] concordant with our observa-
tions that activation of AKT by ARTN leads to
increased expression of TWIST1 in ER-MC cells. Ele-
vated expression of TWIST1 has been correlated with
resistance to the microtubule targeting anticancer drugs
taxol and vincristine [43] and TWIST1 expression is
also increased in MC stem cell-like populations [49].
That increased ARTN expression induces genes asso-
ciated with EMT and stimulates metastasis of ER-MC
suggests that it may regulate a cancer stem cell-like sub-
population of cells that possess an enhanced ability to
metastasize to distant organs. Such a notion is concor-
dant with a previous study [50] demonstrating that
mammary carcinoma cell lines (including MDA-MB-
231) contain functional cancer stem cells with meta-
static capacity. In accordance, we have observed that
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Figure 9 TWIST1 is downstream of ARTEMIN (ARTN) stimulated Protein kinase B (AKT) activation in estrogen receptor (ER) negative
mammary carcinoma (ER-MC). (a) Western blot analyses for ARTN, TWIST1, phospho AKT (pAKT-Ser473) and AKT in BT549 cells with forced
expression of TWIST1 ± siARTN. b-ACTIN was used as loading control for cell lysates. The sizes of detected protein bands in kiloDalton (kDa) are
shown on the right. (b) Colony formation in soft agar. (c) Cell growth (number) in 3D matrigel culture. (d) Cell migration, and (e) Cell invasion
was determined for BT549-TWIST1 cells ± siARTN. siRNA control-treated vector (VEC) cells are presented as 100%. **, P < 0.01; ***, P < 0.001.
Banerjee et al. Breast Cancer Research 2011, 13:R112
http://breast-cancer-research.com/content/13/6/R112
Page 17 of 20forced expression of ARTN in ER-MC cells increased a
sub-population of cells with cancer stem cell-like beha-
vior and enhanced in vivo tumor initiating capability
(manuscript in preparation). ARTN and TWIST1 may
therefore functionally synergize in aspects of mammary
carcinoma cell behavior other than EMT and metastasis
reported herein.
Conclusions
Although ARTN is an estrogen-regulated gene we have
demonstrated that it also mediates oncogenic effects in
ER-MC including cell invasion and metastasis. Func-
tional involvement of GDNF family ligands has not been
previously reported in ER-MC and the identified inter-
actions with TWIST1 provide a novel therapeutic
opportunity for this MC subtype. Furthermore, examina-
tion of the combined expression of ARTN and TWIST1
in ER-MC provides a powerful predictor of survival in
these patients. It is therefore warranted that combina-
torial therapeutic approaches to inhibit both ARTN sig-
nalling and PI3K/AKT, leading to reduced TWIST1, be
considered to improve prognosis in patients with ER-
MC.
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